When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
KPTI - Karyopharm reports positive results from Phase 2b SADAL data for selinexor in patients with DLBCL
Karyopharm Therapeutics Inc.
Karyopharm Therapeutics (NASDAQ:KPTI) reports positive top-line results from the Phase 2b SADAL (Selinexor Against Diffuse Aggressive Lymphoma) study evaluating selinexor, an, oral Selective Inhibitor of Nuclear Export (SINE) compound, in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The data was presented at ASH 2018.
More news on: Karyopharm Therapeutics Inc., Healthcare stocks news,